InMed Pharmaceuticals Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
InMed Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2024.
  • InMed Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.68M, a 33.9% increase year-over-year.
  • InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$7.68M, a 3.42% increase from 2023.
  • InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.95M, a 57.3% increase from 2022.
  • InMed Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$18.6M, a 82.3% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$7.68M +$272K +3.42% Jul 1, 2023 Jun 30, 2024 10-K 2024-09-30
2023 -$7.95M +$10.7M +57.3% Jul 1, 2022 Jun 30, 2023 10-K 2024-09-30
2022 -$18.6M -$8.4M -82.3% Jul 1, 2021 Jun 30, 2022 10-K 2023-09-29
2021 -$10.2M -$1.26M -14.1% Jul 1, 2020 Jun 30, 2021 10-K 2022-09-23
2020 -$8.94M Jul 1, 2019 Jun 30, 2020 10-K 2021-09-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.